WallStreetZenWallStreetZen

NASDAQ: DRMA
Dermata Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their DRMA stock forecasts and price targets.

Forecast return on equity

Is DRMA forecast to generate an efficient return?

Company
-97.24%
Industry
-20.45%
Market
136.06%
DRMA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DRMA forecast to generate an efficient return on assets?

Company
-83.53%
Industry
-26.01%
DRMA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DRMA earnings per share forecast

What is DRMA's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.25
Avg 2 year Forecast
-$1.55

DRMA revenue forecast

What is DRMA's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$102.0k
Avg 2 year Forecast
$765.0k

DRMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DRMA$1.20N/AN/A
MTNB$0.75N/AN/A
CLGN$0.33N/AN/A
PPCB$2.15N/AN/A
ALZN$1.23$28.00+2,176.42%Buy
View Top Biotech Stocks

Dermata Therapeutics Stock Forecast FAQ

What is DRMA's earnings growth forecast for 2026-2027?

(NASDAQ: DRMA) Dermata Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 105.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,341.06%.

Dermata Therapeutics's earnings in 2026 is -$7,102,676.On average, 3 Wall Street analysts forecast DRMA's earnings for 2026 to be -$9,066,715, with the lowest DRMA earnings forecast at -$8,711,157, and the highest DRMA earnings forecast at -$9,333,383.

In 2027, DRMA is forecast to generate -$6,235,931 in earnings, with the lowest earnings forecast at -$5,991,384 and the highest earnings forecast at -$6,419,340.

If you're new to stock investing, here's how to buy Dermata Therapeutics stock.

What is DRMA's revenue growth forecast for 2026-2027?

(NASDAQ: DRMA) Dermata Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 22.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.26%.

Dermata Therapeutics's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast DRMA's revenue for 2026 to be $410,259, with the lowest DRMA revenue forecast at $394,170, and the highest DRMA revenue forecast at $422,325.

In 2027, DRMA is forecast to generate $3,076,939 in revenue, with the lowest revenue forecast at $2,956,275 and the highest revenue forecast at $3,167,438.

What is DRMA's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: DRMA) forecast ROA is -83.53%, which is lower than the forecast US Biotechnology industry average of -26.01%.

What is DRMA's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: DRMA) Dermata Therapeutics's current Earnings Per Share (EPS) is -$5.31. On average, analysts forecast that DRMA's EPS will be -$2.25 for 2026, with the lowest EPS forecast at -$2.17, and the highest EPS forecast at -$2.32. In 2027, DRMA's EPS is forecast to hit -$1.55 (min: -$1.49, max: -$1.60).

What is DRMA's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: DRMA) forecast ROE is -97.24%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.